Thursday, May 27, 2021
6:00PM – 7:00PM ET
Please note this TeleECHO program is 6:00PM Eastern, 5:00PM, Central, 4:00PM Mountain and 3:00PM Pacific
Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.
The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.
Robert G. Gish, MD, FAASLD, AGAF, FAST
Professor of Medicine, Loma Linda University, Liver Transplant Institute, Las Vegas, NV Principal, Robert G Gish Consultants, LLC
Adjunct Professor of Medicine, University of Nevada, Reno
Adjunct Professor of Medicine, University of Nevada, Las Vegas
Adjunct Professor of Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences
University of California, San Diego
Medical Director, Hepatitis B Foundation, Doylestown, PA
After completing the CME activity, learners should be better able to:
- Review mechanisms of action and clinical profiles of immunotherapies used alone or in combination across lines of therapy for the treatment of HCC
- Recognize and manage side effects and toxicities associated with available and emerging immunotherapies used alone or in combination across lines of therapy for the treatment of HCC
- Discuss established and potential prognostic and predictive immune- and non-immune-related biomarkers for HCC and their impact on patient management strategies
- Summarize current recommendations and emerging evidence regarding the use of immunotherapies for patients with HCC during the COVID-19 pandemic including the management of irAEs and the utility of telemedicine
- Explain patient-centered SDM approaches aimed at optimizing cancer care and survivorship for those with HCC and the role of emergency care physicians as part of multidisciplinary teams in the diagnosis and management of irAEs associated with immunotherapies used alone or in combination
This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtual live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual live activity.
NURSING CREDIT INFORMATION
Ultimate Medical Academy/Conference Complete Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This program would be beneficial for nurses involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy
1.0 ANCC Contact Hour
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at email@example.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at firstname.lastname@example.org
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.